Myeloid-derived suppressor cells in glioma

Expert Review of Neurotherapeutics

Volumn 13, Issue 12, 2013, Pages 1395-1406

  Mirghorbani, Masoud ^a   Van Gool, Stefaan ^b   Rezaei, Nima ^a,c,d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

glioblastoma; glioma; myeloid derived suppressor cells

Indexed keywords

(S) (2 BORONOETHYL) L CYSTEINE; 1D 11; 1D11; 2 (5 CHLORO 2 FLUOROPHENYL) 4 (4 PYRIDINYLAMINO)PTERIDINE; 2(S) AMINO 6 BORONOHEXANOIC ACID; 4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; 4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ACETYLSALICYLIC ACID; ANTIHISTAMINIC AGENT; APTAMER; CALGRANULIN A; CALGRANULIN B; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CELECOXIB; CHEMOKINE RECEPTOR ANTAGONIST; CPG OLIGODEOXYNUCLEOTIDE; CURCUMIN; GAMMA INTERFERON; INTERLEUKIN 4 RECEPTOR ALPHA APTAMER; N HYDROXY NOR ARGININE; SECONDARY LYMPHOID TISSUE CHEMOKINE; SORAFENIB; SUNITINIB; SURAMIN; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; BONE MARROW CELL; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL MIGRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNE DEFICIENCY; LOW DRUG DOSE; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NATURAL KILLER T CELL; PHASE 2 CLINICAL TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; T CELL DEPLETION; T LYMPHOCYTE; TREATMENT RESPONSE;

ANIMALS; CELL- AND TISSUE-BASED THERAPY; GLIOMA; HUMANS; IMMUNOSUPPRESSION; MYELOID CELLS; NEOPLASM RECURRENCE, LOCAL; T-LYMPHOCYTES;

EID: 84887875793     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2013.857603     Document Type: Review

References (146)

1. Holland EC. Progenitor cells and glioma formation. Curr. Opin. Neurol. 14(6), 683-688 (2001
2. Surawicz TS, Davis F, Freels S, Laws ER Jr, Menck HR. Brain tumor survival: Results from the National Cancer Data Base. J. Neurooncol. 40(2), 151-160 (1998
3. Ohgaki H, Kleihues P Epidemiology and etiology of gliomas. Acta Neuropathol. 109(1), 93-108 (2005
4. Stupp R, Hegi ME, Mason WP et al Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 459-466 (2009
5. Lefranc F, Sadeghi N, Camby I, Metens T, Dewitte O, Kiss R. Present and potential future issues in glioblastoma treatment. Expert Rev. Anticancer Ther. 6(5), 719-732 (2006
6. Batich K, Choi B, Mitchell D. Immunotherapy of high-grade gliomas: Preclinical in vivo experiments in animal models. In: Animal Models of Brain Tumors. Marti'nez Murillo R, Marti'nez A (Eds). Humana Press, New York, NY, USA, 245-273 (2013
7. Liau LM, Black KL, Prins RM et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J. Neurosurg. 90(6), 1115-1124 (1999
8. Parney IF, Petruk KC, Zhang C, Farr-Jones M, Sykes DB, Chang LJ. Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/ beige mouse-human glioblastoma multiforme model. Hum. Gene Ther. 8(9), 1073-1085 (1997
9. Sampson JH, Archer GE, Ashley DM et al. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc. Natl Acad. Sci. USA 93(19), 10399-10404 (1996
10. Liau LM, Prins RM, Kiertscher SM et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin. Cancer Res. 11(15), 5515-5525 (2005
11. Parney IF, Chang LJ, Farr-Jones MA, Hao C, Smylie M, Petruk KC. Technical hurdles in a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomas. J. Neurooncol. 78(1), 71-80 (2006
12. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 64(14), 4973-4979 (2004
13. Ardon H, Van Gool SW, Verschuere T et al. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: Results of the HGG-2006 phase I/II trial. Cancer Immunol. Immunother. 61(11), 2033-2044 (2012
14. De Vleeschouwer S, Ardon H, Van Calenbergh F et al. Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination. Cancer Immunol. Immunother. 61(11), 2105-2112 (2012
15. Rodrigues JC, Gonzalez GC, Zhang L et al Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol. 12(4), 351-365 (2010
16. Hanahan D, Weinberg RAHallmarks of cancer: The next generation. Cell 144(5), 646-674 (2011
17. Gomez GG, Kruse CA. Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther. Mol. Biol. 10(A), 133-146 (2006
18. Parney IF, Farr-Jones MA, Chang LJ, Petruk KCHuman glioma immunobiology in vitro: Implications for immunogene therapy. Neurosurgery 46(5), 1169-1177, discussion 1177-1178 (2000
19. Vandenberk L, Van Gool SW
20. Sonabend AM, Rolle CE, Lesniak MS The role of regulatory T cells in malignant glioma. Anticancer Res. 28(2B), 1143-1150 (2008
21. Hao C, Parney IF, Roa WH, Turner J, Petruk KC, Ramsay DA. Cytokine and cytokine receptor mRNA expression in human glioblastomas: Evidence of Th1, Th2 and Th3 cytokine dysregulation. Acta Neuropathol. 103(2), 171-178 (2002
22. Morimura T, Neuchrist C, Kitz K et al Monocyte subpopulations in human gliomas: Expression of Fc and complement receptors and correlation with tumor proliferation. Acta Neuropathol. 80(3), 287-294 (1990
23. Parney IF, Waldron JS, Parsa AT. Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation. J. Neurosurg. 110(3), 572-582 (2009
24. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB The role of human glioma-infiltrating microglia/ macrophages in mediating antitumor immune responses. Neuro Oncol. 8(3), 261-279 (2006
25. Flugel A, Labeur MS, Grasbon-Frodl EM, Kreutzberg GW, Graeber MB. Microglia only weakly present glioma antigen to cytotoxic T cells. Int. J. Dev. Neurosci. 17(5-6), 547-556 (1999
26. Taniguchi Y, Ono K, Yoshida S, Tanaka R. Antigen-presenting capability of glial cells under glioma-harboring conditions and the effect of glioma-derived factors on antigen presentation. J. Neuroimmunol. 111(1-2), 177-185 (2000
27. Wagner S, Czub S, Greif M et al. Microglial/macrophage expression of interleukin 10 in human glioblastomas. Int. J. Cancer 82(1), 12-16 (1999
28. Badie B, Schartner J, Prabakaran S, Paul J, Vorpahl J. Expression of Fas ligand by microglia: Possible role in glioma immune evasion. J. Neuroimmunol. 120(1-2), 19-24 (2001
29. Prins RM, Scott GP, Merchant RE, Graf MR. Irradiated tumor cell vaccine for treatment of an established glioma. II. Expansion of myeloid suppressor cells that promote tumor progression. Cancer Immunol. Immunother. 51(4), 190-199 (2002
30. Jia W, Jackson-Cook C, Graf MR. Tumorinfiltrating, myeloid-derived suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat glioma + vaccination model. J. Neuroimmunol. 223(1-2), 20-30 (2010
31. Almand B, Clark JI, Nikitina E et al. Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer. J. Neuroimmunol. 166(1), 678-689 (2001
32. Mirza N, Fishman M, Fricke I et al All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 66(18), 9299-9307 (2006
33. Cohen PA, Ko JS, Storkus WJ et al. Myeloid-derived suppressor cells adhere to physiologic STAT3-vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape. Immunol. Invest. 41(6-7), 680-710 (2012
34. Zhu B, Bando Y, Xiao S et al. CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J. Immunol. 179(8), 5228-5237 (2007
35. Makarenkova VP, Bansal V, Matta BM, Perez LA, Ochoa JB. CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J. Immunol. 176(4), 2085-2094 (2006
36. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 16(1), 53-65 (2006
37. Meyer C, Sevko A, Ramacher M et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc. Natl Acad. Sci. USA 108(41), 17111-17116 (2011
38. Dolcetti L, Peranzoni E, Ugel S et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur. J. Immunol. 40(1), 22-35 (2010
39. Fujita M, Kohanbash G, Fellows-Mayle W et al COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res. 71(7), 2664-2674 (2011
40. Fujita M, Scheurer ME, Decker SA et al. Role of type 1 IFNs in antiglioma immunosurveillance-using mouse studies to guide examination of novel prognostic markers in humans. Clin. Cancer Res. 16(13), 3409-3419 (2010
41. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9(3), 162-174 (2009
42. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181(8), 5791-5802 (2008
43. Mandruzzato S, Solito S, Falisi E et al. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J. Immunol. 182(10), 6562-6568 (2009
44. Filipazzi P, Valenti R, Huber V et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 25(18), 2546-2553 (2007
45. Schmielau J, Finn OJ Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 61(12), 4756-4760 (2001
46. Zea AH, Rodriguez PC, Atkins MB et al Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: A mechanism of tumor evasion. Cancer Res. 65(8), 3044-3048 (2005
47. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 70(11), 4335-4345 (2010
48. Gowda M, Godder K, Kmieciak M et al. Distinct signatures of the immune responses in low risk versus high risk neuroblastoma. J. Transl. Med. 9, 170 (2011
49. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat. Immunol. 11(10), 889-896 (2010
50. Fridlender ZG, Sun J, Kim S et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 16(3), 183-194 (2009
51. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12(4), 253-268 (2012
52. Corzo CA, Condamine T, Lu L et al. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 207(11), 2439-2453 (2010
53. Fridlender ZG, Sun J, Mishalian I et al. Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PLoS ONE 7(2), e31524 (2012
54. Umemura N, Saio M, Suwa T et al. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1-and M2-type characteristics. J. Leukoc. Biol. 83(5), 1136-1144 (2008
55. Movahedi K, Guilliams M, Van Den Bossche J et al Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111(8), 4233-4244 (2008
56. Maes W, Verschuere T, Van Hoylandt A, Boon L, Van Gool S. Depletion of regulatory T cells in a mouse experimental glioma model through anti-CD25 treatment results in the infiltration of non-immunosuppressive myeloid cells in the brain. Clin. Dev. Immunol. 2013, 952469 (2013
57. Zhu X, Fujita M, Snyder LA, Okada H. Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. J. Neurooncol. 104(1), 83-92 (2011
58. Raychaudhuri B, Rayman P, Ireland J et al Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol. 13(6), 591-599 (2011
59. Sippel TR, White J, Nag K et al. Neutrophil degranulation and immunosuppression in patients with GBM: Restoration of cellular immune function by targeting arginase I. Clin. Cancer Res. 17(22), 6992-7002 (2011
60. Rotondo R, Barisione G, Mastracci L et al. IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer. Int. J. Cancer 125(4), 887-893 (2009
61. Liu CY, Wang YM, Wang CL et al. Population alterations of L-arginase-and inducible nitric oxide synthase-expressed CD11b+/CD14(-)/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 136(1), 35-45 (2010
62. Rong Y, Durden DL, Van Meir EG, Brat DJ. 'Pseudopalisading' necrosis in glioblastoma: A familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J. Neuropathol. Exp. Neurol. 65(6), 529-539 (2006
63. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin. Cancer Res. 14(21), 6735-6741 (2008
64. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172(2), 989-999 (2004
65. Rodriguez PC, Ernstoff MS, Hernandez C et al Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 69(4), 1553-1560 (2009
66. Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ immunosuppressive tumour network: Myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 138(2), 105-115 (2013
67. Kotsakis A, Harasymczuk M, Schilling B, Georgoulias V, Argiris A, Whiteside TL. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J. Immunol. Methods 381(1-2), 14-22 (2012
68. Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, Ochoa AC. Regulation of T cell receptor CD3zeta chain expression by L-arginine. J. Biol. Chem. 277(24), 21123-21129 (2002
69. Corzo CA, Cotter MJ, Cheng P et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J. Immunol. 182(9), 5693-5701 (2009
70. Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 24(6), 302-306 (2003
71. Xia Y, Roman LJ, Masters BS, Zweier JL. Inducible nitric-oxide synthase generates superoxide from the reductase domain. J. Biol. Chem. 273(35), 22635-22639 (1998
72. Hildeman DA, Mitchell T, Aronow B, Wojciechowski S, Kappler J, Marrack P. Control of Bcl-2 expression by reactive oxygen species. Proc. Natl Acad. Sci. USA 100(25), 15035-15040 (2003
73. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 70(1), 68-77 (2010
74. Ishii I, Akahoshi N, Yu XN et al. Murine cystathionine gamma-lyase: Complete cDNA and genomic sequences, promoter activity, tissue distribution and developmental expression. Biochem. J. 381(Pt. 1), 113-123 (2004
75. Arner ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 267(20), 6102-6109 (2000
76. Angelini G, Gardella S, Ardy M et al. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc. Natl Acad. Sci. USA 99(3), 1491-1496 (2002
77. Bingisser RM, Tilbrook PA, Holt PG, Kees UR. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J. Immunol. 160(12), 5729-5734 (1998
78. Mazzoni A, Bronte V, Visintin A et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 168(2), 689-695 (2002
79. Harari O, Liao JK. Inhibition of MHC II gene transcription by nitric oxide and antioxidants. Curr. Pharm. Des. 10(8), 893-898 (2004
80. Rivoltini L, Carrabba M, Huber V et al. Immunity to cancer: Attack and escape in T lymphocyte-tumor cell interaction. Immunol. Rev. 188, 97-113 (2002
81. Molon B, Ugel S, Del Pozzo F et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J. Exp. Med. 208(10), 1949-1962 (2011
82. Nagaraj S, Youn JI, Gabrilovich DI. Reciprocal Relationship between Myeloid-Derived Suppressor Cells and T Cells. J. Immunol. 191(1), 17-23 (2013
83. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J. Immunol. 166(9), 5398-5406 (2001
84. Sinha P, Clements VK, Ostrand-Rosenberg S Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res. 65(24), 11743-11751 (2005
85. Huang B, Pan PY, Li Q et al Gr-1+CD115 + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66(2), 1123-1131 (2006
86. Nagaraj S, Gabrilovich DI Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 68(8), 2561-2563 (2008
87. Nagaraj S, Gupta K, Pisarev V et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 13(7), 828-835 (2007
88. Lu T, Ramakrishnan R, Altiok S et al. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J. Clin. Invest. 121(10), 4015-4029 (2011
89. Morford LA, Elliott LH, Carlson SL, Brooks WH, Roszman TL. T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J. Immunol. 159(9), 4415-4425 (1997
90. Dix AR, Brooks WH, Roszman TL, Morford LA. Immune defects observed in patients with primary malignant brain tumors. J. Neuroimmunol. 100(1-2), 216-232 (1999
91. Fecci PE, Mitchell DA, Whitesides JF et al Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 66(6), 3294-3302 (2006
92. Macdonald KP, Rowe V, Clouston AD et al. Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells. J. Immunol. 174(4), 1841-1850 (2005
93. Jacobs JF, Nierkens S, Figdor CG, De Vries IJ, Adema GJ Regulatory T cells in melanoma: The final hurdle towards effective immunotherapy? Lancet Oncol. 13(1), e32-42 (2012
94. Chen W, Jin W, Hardegen N et al. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198(12), 1875-1886 (2003
95. Yu P, Lee Y, Liu W et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med. 201(5), 779-791 (2005
96. Ghiringhelli F, Puig PE, Roux S et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 202(7), 919-929 (2005
97. Kim YC, Bhairavabhotla R, Yoon J et al Oligodeoxynucleotides stabilize Helios-expressing Foxp3+ human T regulatory cells during in vitro expansion. Blood 119(12), 2810-2818 (2012
98. Thornton AM, Korty PE, Tran DQ et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J. Immunol. 184(7), 3433-3441 (2010
99. Yadav M, Louvet C, Davini D et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J. Exp. Med. 209(10), 1713-1722, S1711-1719 (2012
100. Weiss JM, Bilate AM, Gobert M et al. Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells. J. Exp. Med. 209(10), 1723-1742, S1721 (2012
101. Yang R, Cai Z, Zhang Y, Yutzy WHT, Roby KF, Roden RB CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res. 66(13), 6807-6815 (2006
102. Serafini P, Mgebroff S, Noonan K, Borrello I Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68(13), 5439-5449 (2008
103. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J. Immunol. 182(1), 240-249 (2009
104. Liu C, Yu S, Kappes J et al Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 109(10), 4336-4342 (2007
105. Hoechst B, Voigtlaender T, Ormandy L et al Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50(3), 799-807 (2009
106. Oberlies J, Watzl C, Giese T et al. Regulation of NK cell function by human granulocyte arginase. J. Immunol. 182(9), 5259-5267 (2009
107. Alizadeh D, Zhang L, Brown CE, Farrukh O, Jensen MC, Badie B. Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy. Clin. Cancer Res. 16(13), 3399-3408 (2010
108. Hix LM, Shi YH, Brutkiewicz RR, Stein PL, Wang CR, Zhang M. CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis. PLoS ONE 6(6), e20702 (2011
109. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat. Rev. Immunol. 12(4), 239-252 (2012
110. Ambrosino E, Terabe M, Halder RC et al. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: A new immunoregulatory axis. J. Immunol. 179(8), 5126-5136 (2007
111. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198(2), 267-279 (2003
112. Crane CA, Han SJ, Barry JJ, Ahn BJ, Lanier LL, Parsa AT TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol. 12(1), 7-13 (2010
113. Ko HJ, Lee JM, Kim YJ, Kim YS, Lee KA, Kang CY. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: An alternative cell-based antitumor vaccine. J. Immunol. 182(4), 1818-1828 (2009
114. Kohanbash G, Okada H. Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development. Immunol. Invest. 41(6-7), 658-679 (2012
115. Ko JS, Zea AH, Rini BI et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 15(6), 2148-2157 (2009
116. Cao M, Xu Y, Youn JI et al. Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. Lab. Invest. 91(4), 598-608 (2011
117. Wu L, Du H, Li Y, Qu P, Yan C. Signal transducer and activator of transcription 3 (Stat3C) promotes myeloid-derived suppressor cell expansion and immune suppression during lung tumorigenesis. Am. J. Pathol. 179(4), 2131-2141 (2011
118. Roth F, De La Fuente AC, Vella JL, Zoso A, Inverardi L, Serafini P Aptamer-mediated blockade of IL4Ralpha triggers apoptosis of MDSCs and limits tumor progression. Cancer Res. 72(6), 1373-1383 (2012
119. Pak AS, Ip G, Wright MA, Young MR Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy. Cancer Res. 55(4), 885-890 (1995
120. Zoglmeier C, Bauer H, Norenberg D et al. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin. Cancer Res. 17(7), 1765-1775 (2011
121. Okada H, Kalinski P, Ueda R et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 29(3), 330-336 (2011
122. Zhu X, Nishimura F, Sasaki K et al. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J. Transl. Med. 5, 10 (2007
123. Tu SP, Jin H, Shi JD et al. Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. Cancer Prev. Res. 5(2), 205-215 (2012
124. Yoshimura T, Robinson EA, Tanaka S, Appella E, Kuratsu J, Leonard EJ. Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J. Exp. Med. 169(4), 1449-1459 (1989
125. Gebhardt C, Nemeth J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem. Pharmacol. 72(11), 1622-1631 (2006
126. Murat A, Migliavacca E, Hussain SF et al Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. PLoS ONE 4(6), e5947 (2009
127. Baggio R, Emig FA, Christianson DW, Ash DE, Chakder S, Rattan S. Biochemical and functional profile of a newly developed potent and isozyme-selective arginase inhibitor. J. Pharmacol. Exp. Ther. 290(3), 1409-1416 (1999
128. Berkowitz DE, White R, Li D et al Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 108(16), 2000-2006 (2003
129. Santhanam L, Christianson DW, Nyhan D, Berkowitz DE. Arginase and vascular aging. J. Appl. Physiol. 105(5), 1632-1642 (2008
130. Yang XD, Ma JY, Barger MW, Ma JK. Transport and utilization of arginine and arginine-containing peptides by rat alveolar macrophages. Pharm. Res. 19(6), 825-831 (2002
131. Scheurer ME, El-Zein R, Thompson PA et al. Long-term anti-inflammatory and antihistamine medication use and adult glioma risk. Cancer Epidemiol. Biomarkers Prev. 17(5), 1277-1281 (2008
132. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 67(9), 4507-4513 (2007
133. Rodriguez PC, Quiceno DG, Ochoa AC L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109(4), 1568-1573 (2007
134. Bierie B, Moses HL Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev. 21(1), 49-59 (2010
135. Laterra JJ, Grossman SA, Carson KA et al Suramin and radiotherapy in newly diagnosed glioblastoma: Phase 2 NABTT CNS Consortium study. Neuro Oncol. 6(1), 15-20 (2004
136. Grossman SA, Phuphanich S, Lesser G et al. Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas. J. Clin. Oncol. 19(13), 3260-3266 (2001
137. Hjelmeland MD, Hjelmeland AB, Sathornsumetee S et al. SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol. Cancer Ther. 3(6), 737-745 (2004
138. Uhl M, Aulwurm S, Wischhusen J et al SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 64(21), 7954-7961 (2004
139. Yang XD, Ai W, Asfaha S et al. Histamine deficiency promotes inflammation-associated carcinogenesis through reduced myeloid maturation and accumulation of CD11b +Ly6G+ immature myeloid cells. Nat. Med. 17(1), 87-95 (2011
140. Scheurer ME, Amirian ES, Davlin SL, Rice T, Wrensch M, Bondy ML. Effects of antihistamine and anti-inflammatory medication use on risk of specific glioma histologies. Int. J. Cancer 129(9), 2290-2296 (2011
141. Prosniak M, Harshyne LA, Andrews DW et al. Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers. Clin. Cancer Res. 19(14), 3776-3786 (2013
142. Kjellman C, Olofsson SP, Hansson O et al. Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int. J. Cancer 89(3), 251-258 (2000
143. Nitta T, Hishii M, Sato K, Okumura K Selective expression of interleukin-10 gene within glioblastoma multiforme. Brain Res. 649(1-2), 122-128 (1994
144. Wei J, Barr J, Kong LY et al. Glioma-associated cancer-initiating cells induce immunosuppression. Clin. Cancer Res. 16(2), 461-473 (2010
145. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C et al. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin. Cancer Res. 14(16), 5166-5172 (2008
146. Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J. Pathol. 216(1), 15-24 (2008